Showing 5061-5070 of 8126 results for "".
- Samsung Biologics to Manufacture Sun Pharma's Tildrakizumab for Psoriasishttps://practicaldermatology.com/news/samsung-biologics-to-manufacture-sun-pharmas-tildrakizumab-for-psoriasis/2458130/Sun Pharmaceutical Industries just inked a long-term agreement with South Korea’s Samsung BioLogics to manufacture Tildrakizumab for psoriasis. The investigational IL-23p19 inhibitor drug is currently under review by the US Food & Drug Admi
- Aclaris Initiates Phase 2b Trials of A-101 for Topical Treatment of Common Wartshttps://practicaldermatology.com/news/aclaris-initiates-phase-2b-trials-of-a-101-for-topical-treatment-of-common-warts/2458135/Aclaris Therapeutics, Inc. has initiated two Phase 2 clinical trials to evaluate A-101 45% topical solution (A-101 45%), an investigational drug for the treatment of common warts (verruca vulgaris). Over 22 million Americans have common warts, but there are currently no FDA-approved prescription
- Thumbs Down for Neothetics, Inc.'s LIPO-202; Stock Plummetshttps://practicaldermatology.com/news/thumbs-down-for-neothetics-incs-lipo-202/2458145/Neothetics, Inc.’s LIPO-202 for the reduction of submental subcutaneous fat failed to demonstrate improvement on any efficacy measurements or separation from placebo in a Phase 2 proof-of-concept trial. Neothetics Inc. shares droppe
- Cynosure's SculpSure Cleared for Back, Inner and Outer Thighshttps://practicaldermatology.com/news/cynosures-sculpsure-cleared-for-back-inner-and-outer-thighs/2458155/The U.S. Food and Drug Administration (FDA) granted an expanded clearance for Cynosure's SculpSure to treat the back and inner and outer thighs. The SculpSure treatment is already FDA-cleared for treatment of the abdomen an
- PsA Patients Failing Anti-TNF Drugs May Do Well on Taltzhttps://practicaldermatology.com/news/psa-patients-who-fail-anti-tnf-drugs-may-do-well-on-taltz/2458154/New data show that Taltz (ixekizumab) improved the signs and symptoms of active psoriatic arthritis (PsA) in patients who had inadequate response to one or two TNF inhibitors or were intolerant of TNF inhibitors treated. Eli Lilly has filed a supple
- And Then There Were Three: Alma Lasers Inc. Hair Removal Platform Now Comprises Three Wavelengthshttps://practicaldermatology.com/news/and-then-there-were-three-alma-lasers-inc-hair-removal-platform-now-comprises-three-wavelengths/2458158/Alma Lasers now offers 1064 Nd: YAG capabilities along with 810nm and 755nm on its Soprano ICE platform, allowing users to better match wavelength to hair removal patient. Alma added Alexandrite technology to its Soprano ICE platform in 2014 for
- FDA Warns Public About Black Henna Tattoo Riskshttps://practicaldermatology.com/news/fda-warns-public-about-black-henna-tattoo-risks/2458159/Black henna temporary tattoos can cause serious skin reactions, the US Food and Drug Administration (FDA) warns. For centuries, traditional henna, a reddish-brown plant extract, has been used to dye skin, hair, and fingernails in parts of Asia and Northern Africa. Henna is
- EMA Grants Orphan Status to Tarix's EB Candidiatehttps://practicaldermatology.com/news/ema-grants-orphan-status-to-tarixs-eb-candidiate/2458160/The European Medicines Agency (EMA) granted Orphan Drug status to Tarix Orphan LLC’s lead compound, TXA127, for the treatment of epidermolysis bullosa (EB). TXA127 is a pharmaceutical grade formulation of the naturally occurring peptide
- Murad Adds Two New Blemish-busting Products for Acne Awareness Monthhttps://practicaldermatology.com/news/murad-adds-two-new-products-for-acne-awareness-month/2458161/June is acne awareness month, and Murad is rolling out two anti-acne new products to help patients say goodbye to blemishes. The new Pore Extractor Pomegranate Mask ($38 from Murad.com) features volcanic clay, pomegranate extract and lactic aci
- Retailers Charge Women More Than Men for Minoxidilhttps://practicaldermatology.com/news/retailers-charge-women-more-than-men-for-minoxidil/2458163/Women pay an average of 40 percent more than men for minoxidil foams, according to a new analysis from researchers at the Perelman School of Medicine at the University of Pennsylvania in JAMA Dermatology</